NCT00001595 2026-04-03
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
National Institutes of Health Clinical Center (CC)
Recruiting
Clinical Trials
28 trialsNCT03665064 2026-03-16
Long Term Outcome Study in Patients With Pituitary Disorders
University of Alberta
Active not recruiting
NCT07463235 2026-03-13
SPARAGMOS
University of Sao Paulo General Hospital
Phase 3 Recruiting
NCT07268183 2026-01-22
OEMacroPrL
Hospices Civils de Lyon
Recruiting
NCT06936813 2026-01-08
The PROMISE Survey
University Hospital, Basel, Switzerland
Active not recruiting
NCT04106531 2025-12-05
Prolac-10
Ohio State University
Terminated
NCT07045935 2025-09-23
ProBOLIC
University Hospital, Basel, Switzerland
Phase 4 Recruiting
NCT03038308 2024-06-04
Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole
Columbia University
Phase 1/2 Completed
NCT05236829 2024-05-24
Exercise Capacity and Physical Activity Level in Prolactinoma Patients
Hacettepe University
Completed
NCT00601289 2020-07-31
Temozolomide in Treating Patients With Invasive Pituitary Tumors
Jonsson Comprehensive Cancer Center
Phase 2 Withdrawn
NCT04107480 2020-07-20
PRolaCT - Three Prolactinoma RCTs
Leiden University Medical Center
Phase 4 Unknown
NCT03457389 2020-03-18
Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma
Seoul National University Hospital
Phase NA Unknown
NCT03474601 2020-03-18
SNU-PIT
Seoul National University Hospital
Unknown
NCT00939523 2020-01-22
Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy
Cedars-Sinai Medical Center
Phase 2 Completed
NCT03717454 2018-11-20
Dopamine D2 Receptors(D2R) Imaging in Prolactinomas
Ruijin Hospital
Phase NA Unknown
NCT03400865 2018-10-16
Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant Prolactinomas
Ruijin Hospital
Phase NA Unknown
NCT01504399 2018-08-22
Rhinological Outcomes in Endonasal Pituitary Surgery
St. Joseph's Hospital and Medical Center, Phoenix
Completed
NCT03353025 2017-11-24
TNAPA
First Affiliated Hospital, Sun Yat-Sen University
Phase NA Unknown
NCT02536261 2017-05-16
Dopamine Agonists Withdrawal Study of Invasive Prolactinomas Involving the Cavernous Sinus
Ruijin Hospital
Unknown
NCT01620138 2016-08-22
Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas
Universidade Federal do Rio de Janeiro
Phase 2/3 Completed
NCT02854228 2016-08-03
PITUICARE-Lyon
Hospices Civils de Lyon
Unknown
NCT01775332 2015-07-31
Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education Tools
Unity Health Toronto
Phase NA Unknown
NCT01088763 2014-11-05
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00598949 2010-12-15
Prevalence of Pituitary Incidentaloma in Relatives of Patients With Pituitary Adenoma
Cedars-Sinai Medical Center
Unknown
NCT01143584 2010-06-14
Efficacy of Rapid Escalation of Cabergoline in Comparison to Conventional Dosing in Prolactin Secreting Macroadenomas.
PIMERIndia
Phase NA Unknown
NCT00697814 2008-06-16
Clomiphene in Males With Prolactinomas and Persistent Hypogonadism
Federal University of São Paulo
Phase 2 Completed
NCT00460616 2008-04-16
ValveCab
Federico II University
Completed
NCT00481299 2007-06-01
Insulin Resistance in Women With Prolactinoma
Universidade Federal do Rio de Janeiro
Completed